Smith & Nephew plc (LON:SN) had its target price increased by research analysts at J P Morgan Chase & Co from GBX 1,361 ($18.08) to GBX 1,382 ($18.36) in a research report issued to clients and investors on Thursday, MarketBeat Ratings reports. The brokerage currently has a “neutral” rating on the stock. J P Morgan Chase & Co’s price objective points to a potential downside of 3.22% from the company’s current price.

Several other analysts have also weighed in on SN. Credit Suisse Group reissued a “neutral” rating and issued a GBX 1,280 ($17.01) price objective on shares of Smith & Nephew plc in a report on Friday, July 28th. Citigroup Inc. reissued a “sell” rating and issued a GBX 1,160 ($15.41) price objective on shares of Smith & Nephew plc in a report on Monday, July 10th. Berenberg Bank reissued a “hold” rating and issued a GBX 1,300 ($17.27) price objective on shares of Smith & Nephew plc in a report on Tuesday, July 18th. HSBC Holdings plc reissued a “hold” rating and issued a GBX 1,320 ($17.54) price objective on shares of Smith & Nephew plc in a report on Monday, July 10th. Finally, Goldman Sachs Group, Inc. (The) reissued a “neutral” rating and issued a GBX 1,380 ($18.34) price objective on shares of Smith & Nephew plc in a report on Friday, June 30th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and three have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of GBX 1,291 ($17.15).

Smith & Nephew plc (SN) traded up 1.06% on Thursday, hitting GBX 1428.00. The stock had a trading volume of 4,764,897 shares. The stock’s market cap is GBX 12.50 billion. Smith & Nephew plc has a one year low of GBX 1,064.91 and a one year high of GBX 1,442.00. The company’s 50-day moving average is GBX 1,374.03 and its 200-day moving average is GBX 1,335.00.

ILLEGAL ACTIVITY NOTICE: “Smith & Nephew plc (SN) Given New GBX 1,382 Price Target at J P Morgan Chase & Co” was published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright laws. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/10/22/smith-nephew-plc-sn-given-new-gbx-1382-price-target-at-j-p-morgan-chase-co.html.

In related news, insider Virginia Bottomley bought 223 shares of the firm’s stock in a transaction on Wednesday, August 16th. The stock was bought at an average cost of GBX 1,380 ($18.34) per share, for a total transaction of £3,077.40 ($4,089.02).

About Smith & Nephew plc

Smith & Nephew plc is a medical technology company. The Company is engaged in developing, manufacturing, marketing and selling medical devices and services. Its products and services include Sports Medicine Joint Repair, Arthroscopic Enabling Technologies (AET), Trauma & Extremities, Other Surgical Businesses, Knee Implants, Hip Implants, Advanced Wound Care, Advanced Wound Bioactives and Advanced Wound Devices.

Analyst Recommendations for Smith & Nephew plc (LON:SN)

Receive News & Ratings for Smith & Nephew plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew plc and related companies with MarketBeat.com's FREE daily email newsletter.